Cencora, Inc. Website

Cencora, Inc.

NYSE-COR

Company Overview

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

  • Name

    Cencora, Inc.

  • CEO

    Robert Mauch

  • Website

    www.cencora.com

  • Sector

    Health Care Providers and Services

  • Year Founded

    1871

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Cencora distributes pharmaceutical products to nearly one-third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.

  • Robust demand for GLP-1 drugs (for diabetes and weight loss) provides a strong tailwind to Cencora's top line and allows the distributor to offer other high-margin services to both manufacturers and customers.

  • Increasing uptake in biosimilars and patent expirations in blockbuster drugs over the next five years present opportunities for Cencora to distribute higher-margin products and lift profits.

Bears Say

  • Reimbursement pressures on pharmacy and provider customers have led to an emphasis on cost containment, pressuring Cencora's profitability.

  • Scrutiny from the public and politicians over exorbitant branded and specialty drug list prices could result in lower price inflation long term, pressuring Cencora's top-line growth.

  • Uncertainty around pharmaceutical-specific tariffs and policies such as most-favored-nation pricing could muddy Cencora's near- and mid-term revenue and earnings power.

Source: Morningstar Analysis - Nov 05, 2025

What's happening

Nov 4, 2025 - Dec 4, 2025

Asbury Automotive Group Faces Challenges Amidst Analyst Upgrades

  • JPMorgan raised its price target for ABG from $230 to $235, indicating potential upside despite an Underweight rating.
  • Barclays initiated coverage with an Equalweight rating and a price target of $275, leading to a significant one-day share increase.
  • Overall market conditions and consumer spending concerns contributed to ABG's underperformance against the S&P 500 and Consumer Discretionary sector benchmarks.

Over the past month, Asbury Automotive Group (ABG) experienced a decline of 1.4%, which is notably worse than the S&P 500's slight drop of 0.3%. This performance suggests that ABG struggled to maintain investor confidence despite receiving some positive analyst coverage during this period. The prevailing sentiment remained bearish due to broader market challenges and specific issues affecting the company.

On November 5, ABG received a bullish signal when JPMorgan raised its price target from $230 to $235 while maintaining an Underweight rating. This adjustment was perceived positively by investors, resulting in a modest increase of 1.6% on that day; however, this optimism did not sustain momentum in subsequent trading sessions.

The most significant boost occurred on November 12 when Barclays analyst John Babcock initiated coverage with an Equalweight rating and set a price target of $275 for ABG shares, which closed at $222.61 prior to this announcement. Following this news, there was a notable jump of 4.1% in share value on that day as investors reacted favorably based on expectations about future performance.

Despite these bullish indicators from analysts, persistent macroeconomic pressures continued to affect consumer discretionary spending and automotive sales specifically throughout the month. These factors significantly contributed to investor caution regarding ABG's growth prospects amidst fluctuating market conditions.

In summary, while moments of positivity were driven by analyst upgrades—particularly highlighted by Barclays' initiation—the overarching narrative reflected challenges faced by Asbury Automotive Group amid broader economic uncertainties leading it to underperform against both the S&P 500 at -1.1% and Consumer Discretionary sector benchmarks; specifically noted at -0.1%.

NYSE:COR